<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02469922</url>
  </required_header>
  <id_info>
    <org_study_id>2013-JC-ORLK-TEP</org_study_id>
    <secondary_id>IDRCB : 2013-A01219-36</secondary_id>
    <nct_id>NCT02469922</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) During Radio-chemotherapy to Treat Otorhinolaryngological Cancer</brief_title>
  <acronym>TEmPoRAL</acronym>
  <official_title>Prospective Study Assessing Predictive Value of 18 F-2-fluoro-2-deoxy-D-glucose Fluorodeoxyglucose (FDG) Positron Emission Tomography During Radio-chemotherapy for Locally Advanced Epidermoid Carcinoma of Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open multicentric study assessing predictive value of 18-FDG PET (SUV max) at 20 Gy during
      radio-chemotherapy, on the loco-regional control after 2 years
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional relapse</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of TEP scan values (Standardized Update Value max, Metabolic Tumor Volume)</measure>
    <time_frame>pretreatment, 15 days, 29 days, 3 months post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Malignant Neoplasm of Head and Neck</condition>
  <condition>Locally Advanced Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Positron emission tomography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two additional PET Scan will be performed at 2 and 4 weeks for the first 30 patients. Then for the other patients only one additional PET-Scan will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron emission tomography</intervention_name>
    <arm_group_label>Positron emission tomography</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy</intervention_name>
    <description>Every patients will be treated with radiochemotherapy as a standard of care</description>
    <arm_group_label>Positron emission tomography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years and ≤ 75 years

          -  invasive epidermoid carcinoma of head and neck (excluding nasopharyngeal), confirmed
             by histology

          -  locally advanced disease (non-metastatic stages AJCC III-IV). AJCC = American Joint
             Committee on Cancer

          -  performance status ECOG ≤ 2. ECOG = Eastern Cooperative Oncology Group

          -  no history of irradiation of the head and neck

          -  start of radiotherapy within 8 weeks after the pretreatment PET Scan

          -  no surgery other than biopsy

          -  pregnancy test: negative for women of childbearing potential

          -  reliable contraception for a childbearing couple, men and woman must have a reliable
             contraception during treatment

          -  signed informed consent form

          -  patient with national health insurance

        Exclusion Criteria:

          -  prior radiotherapy or chemotherapy

          -  history of other cancer except: cutaneous non-melanoma tumor and cervix in situ
             carcinoma

          -  unstable conditions (cardiovascular, renal, pulmonary) or systemic (lupus
             erythematosus, scleroderma)

          -  pregnant patient or patient with breastfeeding

          -  patient unable to give his consent

          -  patient under administrative supervision

          -  patient who participates to another clinical trial on experimental drug

          -  regular follow-up impossible for various reasons (familial, economical, social, ...)

          -  diabetes

          -  accelerated radiotherapy protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Castelli Joël, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Lutte Contre le Cancer Centre Eugène Marquis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre jean Bernard - Rue Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Scorff</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Oncologie St Vincent - Boulevard de la Boutière</name>
      <address>
        <city>Saint Grégoire</city>
        <zip>35460</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 25, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2015</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

